Coagulation factor VIII news

All news on Coagulation factor VIII (also known as Factor VIII, FVIII, and Antihemophilic factor): plants, production capacities, investments and involved companies.

11 July 2026

Novo Nordisk: denecimig (Mim8) shows positive long-term Phase 3 FRONTIER4 results in haemophilia A

Interim FRONTIER4 data show consistent safety and efficacy of denecimig across weekly, biweekly and monthly dosing, with low injection-site reactions and high zero-bleed rates.
26 June 2026

Novo Nordisk to present denecimig and concizumab data at ISTH 2026

Phase‑3 FRONTIER4 interim denecimig data across ages and monthly/biweekly/weekly dosing, plus first paediatric explorer10 concizumab 32‑week results for children up to 11 with inhibitors.

Who will be producing Coagulation factor VIII in the future?

Find out with chemXplore Alpha

Learn more